Panderm (Fluprednidene Acetate, Miconazole Nitrate)

Fluprednidene acetate and miconazole nitrate, the active ingredients in Panderm, are a combination corticosteroid and antifungal presented as a topical formulation for skin use. They treat inflammatory dermatoses and superficial fungal infections in both adults and children.

GNH USA supplies Panderm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union quality standards and is manufactured under GMP conditions, ensuring consistent potency and safety for dermatological applications. It is distributed across diverse patient populations requiring combined anti‑inflammatory and antifungal therapy.

Panderm combines a corticosteroid and an antifungal to address inflammatory and fungal skin conditions.

- Inflammatory dermatoses: reduces redness, swelling, and itching associated with conditions such as eczema and contact dermatitis. - Superficial fungal infections: eliminates dermatophyte growth in tinea corporis, tinea cruris, and tinea pedis. - Seborrheic dermatitis: controls inflammation and yeast overgrowth on scalp and facial skin.

Topical application of Panderm may be associated with local adverse reactions.

Common Side Effects: - Burning sensation: mild transient heat at the application site. - Pruritus: itching that may occur after initial use. - Erythema: mild redness of the skin. - Dryness: localized skin dryness or flaking. - Folliculitis: inflammation of hair follicles.

Serious or Rare Side Effects: - Contact dermatitis: allergic reaction with swelling and rash. - Skin atrophy: thinning of the skin with prolonged use. - Secondary infection: bacterial or viral infection of treated area. - Hypersensitivity reactions: systemic signs such as urticaria or angioedema. - Cushingoid effects: systemic glucocorticoid effects with extensive application.

Before using Panderm, consider the following precautions to ensure safe and effective therapy.

- Indication verification: confirm diagnosis of inflammatory or fungal skin condition before application. - Duration of therapy: limit use to the shortest period necessary, typically no longer than 2‑4 weeks, to reduce risk of steroid‑related side effects. - Application area: avoid use on large body surface areas or under occlusion unless directed by a physician. - Contraindications: do not apply to skin with viral infections (e.g., herpes simplex), bacterial infections, or known hypersensitivity to either component. - Pediatric use: exercise caution in children; monitor for signs of systemic absorption. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Panderm may interact with other topical or systemic agents; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent systemic steroids may increase risk of systemic glucocorticoid effects. - Potent CYP450 inhibitors: drugs that inhibit fungal enzyme pathways may alter miconazole metabolism, though topical exposure is minimal.

Moderate Interactions (Monitor Closely): - Other topical steroids: combined use can enhance local skin thinning. - Antifungal agents: concurrent use may increase local irritation. - Immunosuppressants: patients on systemic immunosuppressants may have higher risk of infection.